Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.70 |
| ▸ | NPY2R | P49146 | 2/20 | 0.70 |
| ▸ | NPY4R | P50391 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymopentin SCHEMBL1651175 | 1.00 | NPY1R (0.70) | NPY1RNPY2RNPY4RSMN1; SMN2AGTR2 | |
| SCHEMBL29363799 | 0.95 | NPY1R (0.70) | NPY1RNPY2RNPY4RSMN1; SMN2NTSR2 | |
| Acetic Acid SCHEMBL29353009 | 0.94 | NPY1R (0.68) | NPY1RNPY2RNPY4RSMN1; SMN2NTSR2 | |
| SCHEMBL29363254 | 0.91 | NPY1R (0.54) | NPY1RNPY2RNPY4RNTSR2NTSR1 | |
| SCHEMBL29735895 | 0.89 | NPY1R (0.53) | NPY1RNPY2RNPY4RNTSR2NTSR1 | |
| SCHEMBL30641532 | 0.88 | NPY1R (0.54) | NPY1RNPY2RNPY4RNTSR2NTSR1 | |
| SCHEMBL27210447 | 0.87 | BACE1 (0.54) | NPY1RNPY2RNPY4R | |
| SCHEMBL27210457 | 0.87 | BACE1 (0.54) | NPY1RNPY2RNPY4R | |
| SCHEMBL29611639 | 0.87 | OPRD1 (0.57) | NPY1RNPY2RNPY4RNTSR2NTSR1 | |
| Thymopentin SCHEMBL989519 | 0.87 | NPY4R (0.62) | NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7172 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4735581-A2 | METHODS OF MAKING AND USING ENGINEERED IMMUNE CELLS | The Regents of University of California (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4704867-A1 | METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS | Sana Biotechnology, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260048086-A1 | METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS | SANA BIOTECHNOLOGY INC (US) | 2026-02-19 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4642761-A1 | BIOREACTIVE PROTEINS CONTAINING AN UNNATURAL AMINO ACID AND ARGININE | The Regents of University of California (US) | 2025-11-05 | — | — | EP | claimed |
| US-12459989-B2 | Antibody therapies for human immunodeficiency virus (HIV) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250325680-A1 | HIGH-PERMEABILITY PROTEIN OR POLYPEPTIDE CONJUGATE AND USE THEREOF | Hangzhou Tito Biotechnology Partnership Enterprise ( Limited Partnership ) (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4631514-A1 | ORAL POLYPEPTIDE COMPOSITION AND USE THEREOF | Hefei Tianhui Biotech Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| EP-0420649-A2 | Stabilized aqueous formulations of small peptides | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1991-04-03 | — | — | EP | claimed |
| EP-0406931-A2 | New analogues of all-bond retroinverted thymopentin, the method for the synthesis of the same and their employment for the preparation of pharmaceutical compositions | SCLAVO S.p.A. (IT) | 1991-01-09 | — | — | EP | claimed |
| EP-0393786-A1 | New retro-inverse, one- or more bond bearing analogues of thymopentin, a method for synthesizing the same and their employment for the preparation of pharmaceutical | SCLAVO S.p.A. (IT) | 1990-10-24 | — | — | EP | claimed |
| WO-1990012029-A1 | LYOPHILIZED PEPTIDE FORMULATIONS | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1990-10-18 | — | — | WO | claimed |
| WO-1990007933-A1 | COMPOSITIONS CONTAINING THYMOPENTIN FOR TOPICAL TREATMENT OF SKIN DISORDERS | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1990-07-26 | — | — | WO | claimed |
| EP-0378413-A2 | Compositions for topical treatment of skin disorders | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1990-07-18 | — | — | EP | claimed |
| WO-1989009229-A1 | TREATMENT OF HIV VIREMIC PATIENTS WITH THYMOPENTIN | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1989-10-05 | — | — | WO | claimed |
| EP-0335726-A2 | Use of thymopentin and derivatives in treatment of HIV viremic patients | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1989-10-04 | — | — | EP | claimed |
| US-4749690-A | ADMINISTERING OLIGOPEPTIDE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-06-07 | — | — | US | claimed |
| EP-0235904-A2 | Treatment of allergy with thymopentin | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-09-09 | — | — | EP | claimed |